Health Trials

Advanced Solid Tumors With MAPK Pathway Mutations

1

Review clinical trials related to Advanced Solid Tumors With MAPK Pathway Mutations. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

This first-in-human (FIH) study aims to assess the safety, tolerability, pharmacokinetics, and recommended phase 2 dose (RP2D) of D3S-002 given orally daily for 21-day cycles in adult subjects with advanced solid tumors with mitogen-activated protein kinase (MAPK) pathway mutations.

Participants needed: 67
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: D3 Bio (Wuxi) Co., LtdUpdated: Jun 8, 2026Locations: 14
Eligibility criteria

Part 1: Subjects must have a histologically or cytologically confirmed metastati... [+14]

Subject has any prior treatment with other treatments without adequate washout p... [+10]

Read more